SCHEDULE: FMR LLC Boosts Day One Bio Stake to 11.2%

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 11.2% in Day One Biopharmaceuticals Inc., holding over 11.3 million shares.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 11,342,699.49 shares of Day One Biopharmaceuticals Inc. common stock.
• This represents 11.2% of the outstanding common stock of Day One Biopharmaceuticals Inc.
• FMR LLC holds sole voting power over 11,339,833.00 shares and sole dispositive power over 11,342,699.49 shares.
• Abigail P. Johnson holds sole dispositive power over 11,342,699.49 shares.
• The filing is an Amendment No. 3 to a Schedule 13G, indicating a change in previously reported beneficial ownership.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of beneficial ownership by a major institutional investor, FMR LLC, and its principal, Abigail P. Johnson. The significant stake of 11.2% in Day One Biopharmaceuticals Inc. is a positive signal of institutional confidence, though the filing itself does not contain operational or financial performance data.

Positives

• Significant institutional ownership by FMR LLC, a major investment management firm, indicating confidence in Day One Biopharmaceuticals Inc.
• The holding represents a substantial 11.2% of the company's common stock.

Future Outlook

This filing is a disclosure of beneficial ownership by an institutional investor and does not contain forward-looking statements or guidance from Day One Biopharmaceuticals Inc.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates continued institutional interest in the biotechnology/pharmaceutical sector, specifically in Day One Biopharmaceuticals Inc., by a major asset manager like FMR LLC.

Stakeholder Impact

• Shareholders: Increased confidence due to significant institutional investment.
• Company: Validation of its business model and potential for increased liquidity.

Key Dates

Keywords

Day One Biopharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceuticals, Institutional Investor